Matt Roberts

could you maybe [Technical Difficulty] the March exit rate looked versus what you saw in April

Was it confined to a certain region or maybe parse out your expectations for the second half of the year between pharma and healthcare more broadly

could you give us sales and EBITDA contribution

how could that impact the procurement synergies given that complementary resin buying was a portion of the buying power there

how has your idea of timing around that pruning changed from when the merger was announced to now

how are your customers looking to offset their own cost via price, and what impact do you expect that to have on the volume outlook going forward?

Is that compliance enforcement coming back in 2026? Or are you expecting any incremental volumes from that customer with further category rollouts?

how much of the initial five points that you expected in 2025 from new programs have shifted into 2026?

Share repurchases to date are near record annual levels, still trading at the valuation gap versus the S&P.

what type of cost impacts or tariff exposures are your suppliers or partners in the RFID value chain facing that could drive cost higher

general retail accelerated in 4Q all the way from 20% to 40%. Maybe you could talk about what drove that acceleration

I know you said that was up mid-single digits. What region was that? Or was that enterprise wide

Could you parse out, I believe you called $35 million cost headwind. Is that still $10 million to $15 million first half from the tariffs and the remainder from Millersburg in second half